



ESC Guidelines

# Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis

## Executive Summary

### The Task Force on Infective Endocarditis of the European Society of Cardiology

**Task Force Members, Dieter Horstkotte, Chairperson\* (Germany), Ferenc Follath (Switzerland), Erno Gutschik (Denmark), Maria Lengyel (Hungary), Ali Oto (Turkey), Alain Pavie (France), Jordi Soler-Soler (Spain), Gaetano Thiene (Italy), Alexander von Graevenitz (Switzerland)**

**ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Maria Angeles Alonso Garcia (Spain), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), Martin Cowie (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Enrique Fernández Burgos (Spain), John Lekakis (Greece), Bertil Lindahl (Sweden), Gianfranco Mazzotta (Italy), João Morais (Portugal), Ali Oto (Turkey), Otto A. Smiseth (Norway)**

**Document Reviewers, John Lekakis, CPG Review Coordinator (Greece), Alec Vahanian (France), François Delahaye (France), Alexander Parkhomenko (Ukraine), Gerasimos Filipatos (Greece), Jan Aldershvile (Denmark), Panos Vardas (Greece)**

#### Table of contents

Preamble .....	267	Empirical therapy .....	271
Introduction .....	268	Special subsets .....	271
Definitions, terminology .....	268	Management of complications .....	271
Prevention of infective endocarditis .....	268	Surgery for active NVE .....	272
Cardiac conditions/patients at risk .....	268	Surgery for active PVE .....	273
Patient-related non-cardiac conditions .....	268	Postoperative antibiotic treatment .....	273
Predisposing diagnostic and therapeutic interventions .....	268	List of Abbreviations .....	273
Prophylactic antibiotic regimens .....	269	Further Reading .....	274
Diagnosis .....	269		
History, symptoms, signs and laboratory tests ....	269		
Echocardiography .....	269		
Standard blood culture techniques .....	270		
Culture-negative endocarditis (CNE) .....	270		
Treatment and management .....	271		
Antimicrobial therapy .....	271		
Drug level monitoring .....	271		

#### Preamble

Guidelines and Expert Consensus documents aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical decision-making.

A great number of Guidelines and Expert Consensus Documents have been issued in recent years by different organizations, the European Society of Cardiology (ESC) and by other related societies. By means of links to web sites of National Societies several hundred guidelines are available. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable

\* Corresponding author: Chairperson: Dieter Horstkotte, MD, FESC, Professor and Head Department of Cardiology, Heart Center North Rhine-Westphalia, Ruhr University Bochum, Georgstr. 11, D-32545 Bad Oeynhausen, Germany. Tel.: +49-5731-971258; Fax: +49-5731-972194  
E-mail address: akohlstaedt@hdz-nrw.de (D. Horstkotte).

decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing Guidelines and Expert Consensus Documents.

In spite of the fact that standards for issuing good quality Guidelines and Expert Consensus Documents are well defined, recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied within the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are easily interpreted. Subsequently, their implementation programmes must also be well conducted. Attempts have been made to determine whether guidelines improve the quality of clinical practice and the utilisation of health resources.

The *ESC Committee for Practice Guidelines (CPG)* supervises and coordinates the preparation of new *Guidelines* and *Expert Consensus Documents* produced by Task Forces, expert groups or consensus panels. The Committee is also responsible for the endorsement of these Guidelines and Expert Consensus Documents or statements.

Level of recommendations and evidence

Strength of recommendation	Definition
Class I	Evidence and/or general agreement that a given treatment or a diagnostic approach is beneficial, useful and effective
Class II	Conflicting evidence and/or a divergence of opinions about the usefulness/efficacy of a treatment or a diagnostic measure
IIa	Weight of evidence/opinion is in favour of usefulness/efficacy
IIb	Usefulness/efficacy is less well established by evidence/opinion
Class III	Evidence or general agreement that the treatment/diagnostic measure is not useful/effective and in some cases may be harmful

Level of evidence	Available evidence
A	At least two randomized trials supporting the recommendation
B	Single randomized trial and/or a meta-analysis of non-randomized studies supporting the recommendation
C	Consensus opinion of experts based on trials and clinical experience

## Introduction

If untreated, Infective Endocarditis (IE) is a fatal disease. Major diagnostic (first of all echocardiography) and therapeutic progress (mainly surgery during active IE) have contributed to some prognostic improvement during the last decades. If the diagnosis is delayed or appropriate therapeutic measures postponed, mortality is still high. In this respect, it is of utmost importance that (a) IE is considered early in every patient with fever or septicaemia and cardiac murmurs; (b) echocardiography is applied without delay in suspected IE; (c), cardiologists, microbiologists and cardiac surgeons cooperate closely if IE is suspected or definite.

## Definitions, terminology

IE is an endovascular, microbial infection of intracardiac structures facing the blood including infections of the large intrathoracic vessels and of intracardiac foreign bodies. The early characteristic lesion is a variably sized vegetation, although destruction, ulceration or abscess formation may be seen earlier by echocardiography.

Terminology (Table 1) should give the following information: (a), activity of the disease and recurrence; (b), diagnostic status; (c), pathogenesis; (d), anatomical site; and (e), microbiology.

## Prevention of infective endocarditis

For prophylactic reasons, antibiotics should be given before a bacteraemia is expected. If antibiotic prophylaxis is not given prior to this event, antibiotics may help a late clearance if administered intravenously within 2–3 h.

## Cardiac conditions/patients at risk

A previous history of IE, the presence of prosthetic heart valves or other foreign material, surgically created conduits, and complex cyanotic congenital abnormalities are considered high-risk situations. Only patients with high or moderate risk (Table 2) should receive prophylaxis. This is a class I recommendation based on level C evidence.

## Patient-related non-cardiac conditions

Older age, conditions (a), promoting non-bacterial thrombotic vegetation; (b), compromising host defense; (c), compromising local non-immune defence mechanisms; and (d), increased risk/frequency/amount of bacteraemia are considered patient related, non-cardiac risk conditions.

## Predisposing diagnostic and therapeutic interventions

Procedures which may cause bacteraemia and for which antimicrobial prophylaxis is recommended are given in Table 3. Prophylaxis is not recommended for cardiac catheterization.

Dental hygiene is of major importance for the prevention of IE.

**Table 1** Terminology for infective endocarditis (IE). Examples: active mitral valve IE due to *Enterococcus faecalis*; healed recurrent prosthetic aortic valve endocarditis due to *Staphylococcus epidermidis*; suspected culture-negative late prosthetic mitral valve endocarditis

	Activity	Recurrence	Diagnostic terminology	Pathology	Anatomical site	Microbiology
First episode <sup>a</sup>	Active healed	Relapsing recurrent			Mitral aortic tricuspid mural etc	Microorganism culture-negative, serologically negative, PCR negative, histologically negative
Definite <sup>a</sup>			Suspected Possible			
Native <sup>a</sup>				Early prosthetic Late prosthetic IVDA <sup>b</sup>		

<sup>a</sup>If the columns 'recurrence', 'diagnostic terminology', and/or 'pathology' are without text, they signify the first episode of IE (not relapsing or recurrent), 'definite' IE (not suspected or possible) and involvement of a native cardiac valve.

<sup>b</sup>Intravenous drug abuse.

**Table 2** Cardiac conditions in which antimicrobial prophylaxis is indicated

- Prosthetic heart valves<sup>a</sup>
- Complex congenital cyanotic heart diseases<sup>a</sup>
- Previous infective endocarditis<sup>a</sup>
- Surgically constructed systemic or pulmonary conduits<sup>a</sup>
- Acquired valvular heart diseases
- Mitral valve prolapse with valvular regurgitation or severe valve thickening
- Non-cyanotic congenital heart diseases (except for secundum type ASD) including bicuspid aortic valves
- Hypertrophic cardiomyopathy

<sup>a</sup>High-risk group (see text).

**Table 3** Diagnostic and therapeutic interventions likely to produce bacteraemia

- bronchoscopy (rigid instrument)
- cystoscopy during urinary tract infection
- biopsy of urinary tract/prostate
- dental procedures with the risk of gingival/mucosal trauma
- tonsillectomy and adenoidectomy
- oesophageal dilation/sclerotherapy
- instrumentation of obstructed biliary tracts
- transurethral resection of prostate
- urethral instrumentation/dilation
- lithotripsy
- gynecologic procedures in the presence of infection

### Prophylactic antibiotic regimens

Prophylaxis aims primarily at viridans streptococci and HACEK organisms before dental, oral, respiratory, and

oesophageal procedures, and at enterococci and *Streptococcus bovis* before gastrointestinal and genitourinary procedures. Despite a lack of convincing evidence antibiotic prophylaxis (Table 4) is a class I recommendation (based on level C evidence).

### Diagnosis

#### History, symptoms, signs and laboratory tests

The diagnosis of IE is established (definite IE) if during a systemic infection involvement of the endocardium is demonstrated. If, in addition, bacteraemia (positive blood cultures) or bacterial DNA are found, IE is definite and culture/microbiologically positive, otherwise IE is definite but culture/microbiologically negative (Table 5). Duke or modified Duke criteria may be used to make the diagnosis in otherwise unclear cases.

#### Echocardiography

Any patient suspected of having NVE by clinical criteria should be screened by transthoracic echocardiography (TTE). When images are of good quality and prove to be negative and there is only a low clinical suspicion of IE, endocarditis is unlikely and other diagnoses are to be considered. If suspicion of IE is high, transoesophageal echocardiography (TEE) should be performed in all TTE-negative cases, in suspected PVE, and if TTE is positive but complications are suspected or likely and before cardiac surgery during active IE. If TEE remains negative and there is still suspicion, it should be repeated within one week. A repeatedly negative study should virtually exclude the diagnosis (Fig. 1). These class I recommendations are based on level B evidence.

Three echocardiographic findings are considered to be major criteria in the diagnosis of IE: (a), a mobile,

**Table 4** Prophylactic antibiotic regimens

- Dental, oral, respiratory, and esophageal procedures (P)
  - not allergic to penicillin
    - amoxicillin 2.0 g (children 50 mg/kg) p.o. 1 h before P
    - **unable to take oral** medication: amoxicillin or ampicillin 2.0 g (children 50 mg/kg) i.v.  $\frac{1}{2}$ –1 h before P
    - **allergic to penicillin**: clindamycin 600 mg (children 20 mg/kg) or azithromycin/clarithromycin 500 mg (children 15 mg/kg) 1 h before P
- Genitourinary and gastrointestinal procedures (P)
  - not allergic to penicillin
    - **high-risk group**: ampicillin or amoxicillin 2.0 g i.v. plus gentamicin 1.5 mg/kg i.v.  $\frac{1}{2}$ –1 h before P; 6 h later, ampicillin or amoxicillin 1.0 g p.o.
    - moderate-risk group: ampicillin or amoxicillin 2.0 g i.v. (children 50 mg/kg)  $\frac{1}{2}$ –1 h before P; or amoxicillin 2.0 g (children 50 mg/kg) p.o. 1 h before P
  - allergic to penicillin
    - **high-risk group**: vancomycin 1.0 g (children 20 mg/kg) over 1–2 h before P plus gentamicin 1.5 mg/kg i.v. or i.m.
    - moderate-risk group: vancomycin (see above) without gentamicin

**Table 5** Criteria that should raise suspicion of IE

- High clinical suspicion (urgent indication for echocardiographic screening and possibly hospital admission)
  - new valve lesion/ (regurgitant) murmur
  - embolic event(s) of unknown origin (esp. cerebral and renal infarction)
  - sepsis of unknown origin
  - haematuria, glomerulonephritis, and suspected renal infarction
  - 'fever' plus
    - prosthetic material inside the heart
    - other high predispositions for IE
    - newly developed ventricular arrhythmias or conduction disturbances
    - first manifestation of CHF
    - positive BCs (if the organism identified is typical for NVE/PVE)
    - cutaneous (Osler, Janeway) or ophthalmic (Roth) manifestations
    - multifocal/rapid changing pulmonic infiltrations (right heart IE)
    - peripheral abscesses (renal, splenic, spine) of unknown origin
    - predisposition and recent diagnostic/therapeutic interventions known to result in significant bacteraemia
- Low clinical suspicion
  - fever plus none of the above

echodense mass attached to the valvular or the mural endocardium or to implanted prosthetic material; (b), demonstration of abscesses or fistulas; (c), a new dehiscence of a valve prosthesis, especially when occurring late after implantation.

### Standard blood culture techniques

Three or more blood cultures (BC) should be taken irrespective of body temperature at least 1 h apart. If the patient has been on short-term antibiotics, one should wait, if possible, at least for three days after discontinuing antibiotic treatment before new BCs are taken. Blood cultures after long-term antibiotic treatment may not become positive after treatment has been discontinued for 6–7 days.

One BC consists of one aerobic and one anaerobic bottle, each containing approx. 50 ml of medium (less in pediatric BC bottles). Venous blood, minimally 5 ml and better 10 ml in adults and 1–5 ml in children should be

added to each bottle. Minimum inhibitory concentrations should be determined for the drugs of choice.

### Culture-negative endocarditis (CNE)

The most frequent cause of CNE is previous antimicrobial treatment. If traditional (non-automatic) BC systems are used, longer incubation periods (>6 days) are required when organisms of the HACEK group, *Propionibacterium* spp., *Neisseria* spp., *Brucella*, *Abiotrophia* spp., or *Campylobacter* spp. are suspected. Especially in CNE all material excised during cardiac surgery for active IE should also be cultured and examined.

The value of serology has been proven for IE due to *Bartonella*, *Legionella*, *Chlamydia* (immunofluorescence) and *Coxiella burnetii*.

The use of broad-spectrum polymerase chain reaction (PCR) provides a significant improvement in the capability to detect difficult-to-culture organisms and even dead bacteria.




Fig. 1 Algorithm for the use of transthoracic (TTE) and transoesophageal echocardiography (TEE) in suspected IE. N.B. TTE "positive" indicates finding typical of IE (e.g. fresh vegetation or abscess formation)

## Treatment and management

### Antimicrobial therapy

For treatment strategies refer to Tables 6–9.

All patients with streptococcal IE should be treated for at least 2 weeks in hospital and observed for cardiac and non-cardiac complications. Patients may then be candidates for outpatient and home parenteral antibiotic therapy. Treatment recommendations for streptococcal IE are based on consistent results of a large number of studies (class I recommendation based on level B evidence).

IE caused by methicillin-resistant *S. aureus* (MRSA) is a therapeutic challenge as most strains are also resistant to most aminoglycosides. If the clinical course is complicated, treatment should be as for PVE.

Coagulase-negative species (CONS) causing PVE within the first year after valve replacement are usually methicillin-resistant. Therapy of choice is a combination of vancomycin and rifampicin for at least 6 weeks with the addition of gentamicin for the initial 2 weeks.

Despite lacking randomized studies and thus level A evidence, the scientific material available is convincing and allows for a class I recommendation.

Enterococci are generally resistant to a wide range of antimicrobial agents including aminoglycosides (MIC for gentamicin 4–64 mg/l). (Table 7)

Duration of treatment should be at least 4 weeks for the combination and at least 6 weeks in complicated cases, in patients having symptoms for more than 3 months, and in patients with PVE. These class IIa recommendations are based on level B evidence.

### Drug level monitoring

Gentamicin trough levels should be less than 0.1 mg/l to avoid renal or ototoxic effects.

Optimum vancomycin effects are achieved if serum concentrations are continuously kept at least 2–4 times above the MIC of the causative organism. Trough levels should be at least 10–15 mg/l. In patients with normal renal function, drug levels should be controlled once, but 2–3 times weekly if combined with aminoglycosides.

### Empirical therapy

In cases complicated by sepsis, severe valvular dysfunction, conduction disturbances, or embolic events, empirical antimicrobial therapy should be started after three blood cultures have been taken (see standard blood culture techniques section).

Recommendations for empirical antibiotic treatment (before microbiologic test results are available) and CNE are given in Table 9.

### Special subsets

Antimicrobial therapy for infections of permanently implanted pacemakers or ICD leads are based on culture and susceptibility results. Duration of therapy should be 4–6 weeks in most cases. Removal of the entire system is generally recommended.

In intravenous drug abusers (IVDAs), a methicillin-susceptible *S. aureus* (MSSA) is the causative organism in about 60–70% of cases. The tricuspid valve is affected in more than 70%. The most common organism (*S. aureus*) must always be covered by the antibiotic regimen. Treatment will include either penicillinase-resistant penicillins or vancomycin, depending on the local prevalence of MRSA. If the patient is a pentazocine addict, an antipseudomonas agent should be added. If IVDAs use brown heroine dissolved in lemon juice, *Candida* should be considered and antifungal treatment added. In IVDAs with underlying valve lesions and/or left-sided involvement, antibiotic treatment against streptococci and enterococci must be added.

### Management of Complications

Rapid and effective antimicrobial treatment may help to prevent embolism. If the patient is on long-term oral anticoagulation, coumarin therapy should be discontinued and replaced by heparin immediately after the diagnosis of IE has been established.

After an embolic complication, the risk for recurrent episodes is high. After manifestation of a cerebral embolism, cardiac surgery to prevent a recurrent episode is not contraindicated if performed early (best within 72 h) and cerebral haemorrhage has been excluded by cranial-computed tomography immediately before the operation. If surgery is not performed early it is advisable to be postponed for 3–4 weeks.

### Surgery for active NVE

The following indications for urgent valve surgery are accepted:

**Table 6** Decision making for antibiotic treatment of native (NVE) and prosthetic valve endocarditis (PVE) due to streptococci

Regimen A NVE; full susceptibility to penicillin (MIC $\leq$ 0.1 mg/l)	
<ul style="list-style-type: none"> <li>patients <math>\leq</math>65 years, normal serum creatinine levels</li> </ul>	penicillin G 12–20 million units/24 h IV, divided into 4–6 doses for 4 weeks plus gentamicin 3 mg/kg/24 h IV (maximum 240 mg/day), divided into 2–3 doses for 2 weeks
<ul style="list-style-type: none"> <li>same conditions as above with uncomplicated courses and rapid clinical response to therapy</li> </ul>	penicillin G 12–20 million units/24 h IV, divided into 4–6 doses for 2 or 4 weeks with ambulatory treatment after 7 days treatment in hospital <sup>a</sup>
<ul style="list-style-type: none"> <li>patients <math>\geq</math>65 years and/or serum creatinine levels elevated or allergy to penicillin</li> </ul>	penicillin G adapted to renal function for 4 weeks or ceftriaxone 2 g/24 h IV <sup>b</sup> as single dose for 4 weeks
<ul style="list-style-type: none"> <li>patients allergic to penicillin and cephalosporins</li> </ul>	vancomycin 30 mg/kg/24 h IV divided into two doses for 4 weeks
Regimen B susceptibility to penicillin (MIC 0.1 mg/l–0.5 mg/l) or PVE	
	penicillin G 20–24 million units/24 h IV divided into 4–6 doses or <sup>b</sup> ceftriaxone 2 g/24 h IV as single dose both for 4 weeks plus gentamicin 3 mg/kg/24 h IV, divided into 2–3 doses for 2 weeks <sup>c</sup> , followed by ceftriaxone 2 g/24 h IV for additional 2 weeks
	vancomycin as single drug treatment for 4 weeks (dosage see above)
Regimen C resistance to penicillin; MIC $>$ 0.5 mg/l <sup>d</sup>	

<sup>a</sup>For 2 weeks regimen see table 5.1.2 of the full version of these guidelines.

<sup>b</sup>Especially for patients allergic to penicillin

<sup>c</sup>2–3 mg/kg netilmicin once daily may be an alternative (peak serum level  $<$ 16 mg/l).

<sup>d</sup>High level resistance (HLR) to penicillin or ceftriaxone (MIC  $>$ 8 mg/l) and HLR to gentamicin (MIC  $>$ 500 mg/l) or resistance to vancomycin or teicoplanin (MIC  $\geq$ 4 mg/l) are rare among strains of streptococci. In such situations, extended susceptibility testing and a close cooperation with the clinical microbiologist are mandatory.

**Table 7** Decision-making for antibiotic treatment of IE due to enterococci and penicillin-resistant streptococci

Penicillin MIC $\leq$ 8 mg/l and for gentamicin MIC $<$ 500 mg/l	Penicillin G, 16–20 million units in 4–6 divided doses plus gentamicin 3 mg/kg, IV, divided in two doses for 4 weeks
Penicillin-allergic patients with penicillin/gentamicin susceptible enterococcal isolates	Vancomycin 30 mg/kg/day IV in two divided doses plus gentamicin (dosage as above) for 6 weeks
Penicillin-resistant strains, MIC $>$ 8 mg/l <sup>a</sup>	Vancomycin plus gentamicin (dosage as above) for 6 weeks
Vancomycin-resistant strains including strains with low resistance to vancomycin (MIC 4–16 mg/l) or high resistance to gentamicin <sup>a</sup>	Assistance of an experienced microbiologist is mandatory. If antimicrobial therapy fails, valve replacement should be considered early

<sup>a</sup>For resistant enterococci treatment with oxazolidinone may be an option but should be initiated only after advice from a reference centre has been taken.

- Heart failure due to acute aortic regurgitation;
- Heart failure due to acute mitral regurgitation;
- Persistent fever and demonstration of bacteremia for more than 8 days despite adequate antimicrobial therapy;
- Demonstration of abscesses, pseudoaneurysms, abnormal communications like fistulas or rupture of one or more valves, conduction disturbances, myocarditis or other findings indicating local spread (locally uncontrolled infection);
- Involvement of microorganisms which are frequently not cured by antimicrobial therapy (e.g. fungi; *Brucella* and *Coxiella*) or microorganisms which have a high potential for rapid destruction of cardiac structures (e.g. *S. lugdunensis*).

If vegetations are larger than 10 mm on the mitral valve or if they are increasing in size despite antibiotic therapy or if they represent mitral kissing vegetations, early surgery should also be considered.

The prognosis of right-sided IE is favourable. Surgery is necessary if tricuspid vegetations are larger than 20 mm after recurrent pulmonary emboli.

### Surgery for active PVE

The following indications are accepted:

- Early PVE (less than 12 months after surgery)

**Table 8** Decision-making for antibiotic treatment of IE due to staphylococci

Regimen A Native valve endocarditis	
MSSA <sup>a</sup> no allergy to penicillin	oxacillin <sup>b</sup> 8–12 g/24 h IV, divided into 3–4 doses for at least 4 weeks <sup>c</sup> plus gentamicin 3 mg/kg/24 h IV (maximum 240 mg/day), divided into 2–3 doses for the first 3–5 days of treatment
MSSA <sup>a</sup> ‘allergy’ to penicillin <sup>d</sup>	vancomycin 30 mg/kg/24 h IV divided into two doses <sup>e</sup> for 4–6 weeks <sup>f</sup> , plus gentamicin 3 mg/kg/24 h IV (maximum 240 mg/day) divided into 2–3 doses for the first 3–5 days of treatment
MRSA <sup>g</sup>	vancomycin 30 mg/kg/24 h IV divided into two doses <sup>e</sup> for 6 weeks
Regimen B Endocarditis involving prosthetic material/cardiac valve prostheses	
MSSA <sup>a</sup>	oxacillin <sup>b</sup> 8–12 g/24 h IV, divided into 3–4 doses plus rifampicin 900 mg/24 h IV divided into three doses, both for 6–8 weeks, plus gentamicin 3 mg/kg/24 h IV (maximum 240 mg/day) divided into 2–3 doses for the first 2 weeks of treatment
MRSA <sup>g</sup> , CONS <sup>h,i</sup>	vancomycin 30 mg/kg/24 h IV divided into two doses <sup>e</sup> for 6 weeks, plus rifampicin 900 mg/24 h IV divided into three doses, plus gentamicin <sup>j</sup> 3 mg/kg/24 h IV (maximum 240 mg/day) divided into 2–3 doses, all for 6–8 weeks

<sup>a</sup>Methicillin-susceptible *S. aureus*.

<sup>b</sup>Or its congeners.

<sup>c</sup>Except for drug addicts for whom a 2-week regimen may be sufficient (see chapters 5.6.3 of the full version of this guideline).

<sup>d</sup>For both, immediate (IgE) type and hypersensitivity reaction during treatment.

<sup>e</sup>Infusion over at least 60 min.

<sup>f</sup>Total treatment duration for patients initially treated with oxacillin should be at least 4 weeks. These patients should not have a second course of gentamicin treatment.

<sup>g</sup>Methicillin-resistant *S. aureus*.

<sup>h</sup>Coagulase-negative staphylococci. In oxacillin-susceptible CONS vancomycin should be replaced by oxacillin.

<sup>i</sup>For resistant staphylococci treatment with oxazolidinone may be an option but should be initiated only after advice from a reference centre has been taken.

<sup>j</sup>If gentamicin susceptibility has been shown in vitro, gentamicin is added in MRSA for the full course but for CONS only for the first 2 weeks of treatment. If the organism is resistant to all aminoglycosides, gentamicin may be substituted by a fluoroquinolone.

**Table 9** Antimicrobial treatment in CNE or if therapy is urgent and the causative organism unidentified

NVE		
Vancomycin	15 mg/kg i.v. every 12 hours <sup>a,b</sup>	4–6 weeks
+Gentamicin	1.0 mg/kg i.v. every 8 h	2 weeks
PVE		
Vancomycin	15 mg/kg i.v. every 12 h	4–6 weeks
+Rifampicin	300–450 mg p.o. every 8 h	4–6 weeks
+Gentamicin	1.0 mg/kg i.v. every 8 h	2 weeks

<sup>a</sup>Maximum 2 g/day; for drug level monitoring see below and full guideline text.

<sup>b</sup>Aminopenicillin may be added.

- Late PVE complicated by prosthesis dysfunction including significant perivalvular leaks or obstruction, persistent positive blood cultures, abscess formation, conduction abnormalities, and large vegetations, particularly if staphylococci are the infecting agents.

### Postoperative antibiotic treatment

A full course of antimicrobial treatment should be completed regardless of the duration of treatment prior to surgery, but at least 7–15 days postoperatively.

### List of Abbreviations

ASD	Atrial septal defect
BC	Blood culture
CNE	Culture-negative endocarditis
CONS	Coagulase-negative staphylococci
HACEK	Group of bacteria consistent of <i>Haemophilus</i> spp., <i>Actinobacillus actinomycetemcomitans</i> , <i>Cardiobacterium hominis</i> , <i>Eikenella corrodens</i> , <i>Kingella kingae</i>
HLR	High level resistance
ICD	Implantable cardioverter defibrillator
IE	Infective endocarditis
IVDA	Intravenous drug abuser
MIC	Minimal inhibitory concentration
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
MSSA	Methicillin-sensitive <i>Staphylococcus aureus</i>
NVE	Native valve endocarditis
PCR	Polymerase chain reaction
PVE	Prosthetic valve endocarditis
spp	Plural of ‘species’
TEE	Transoesophageal echocardiography
TTE	Transthoracic echocardiography

### Further Reading

Refer to full guidelines for complete reference list at [www.escardio.org](http://www.escardio.org)

1. The Endocarditis Working Group of the International Society of Chemotherapy. Pettersson G, Carbon C. Recommendations for

- the surgical treatment of endocarditis. *Clin Microbiol Infect* 1998;4(Suppl 3):S34–46.
2. Renzulli A, Carozza A, Romano G et al. Recurrent infective endocarditis: a multivariate analysis of 21 years of experience. *Ann Thorac Surg* 2001;72:39–43.
  3. Karchmer AW, Gibbons GW. Infections of prosthetic heart valves and vascular grafts. In: Bisno AL, Waldvogel FA, editors. *Infections associated with indwelling medical devices*. 2nd edn Washington DC: American Society for Microbiology; 1994, p. 213.
  4. Horstkotte D, Piper C, Niehues R et al. Late prosthetic valve endocarditis. *Eur Heart J* 1995;16(Suppl B):39–47.
  5. Selton-Suty Ch, Hoen B, Grentzinger A et al. Clinical and bacteriological characteristics of infective endocarditis in the elderly. *Heart* 1997;77:260–3.
  6. Durack DT, Towns ML. Diagnosis and management of infective endocarditis. In: Yusuf S, Camm AJ, Cairns JA et al. (eds), *Evidence Based Cardiology*. BMJ Books 1998:884–904.
  7. Lamas CC, Eykyn SJ. Hospital acquired native valve endocarditis: analysis of 22 cases presenting over 11 years. *Heart* 1998;79:442–7.
  8. Everett ED, Hirschmann JV. Transient bacteremia and endocarditis prophylaxis. A review. *Medicine* 1977;56:61–77.
  9. Strom BL, Abrutyn E., Berlin JA et al. Dental and cardiac risk factors for infective endocarditis. *Ann Intern Med* 1998;129:761–9.
  10. Durack DT. Prevention of infective endocarditis. *N Engl J Med* 1995;332:38–44.
  11. Horstkotte D, Rosin H, Friedrichs W et al. Contribution for choosing the optimal prophylaxis of bacterial endocarditis. *Eur Heart J* 1987;8(Suppl J):379–81.
  12. Dajani AS, Taubert KA, Wilson W et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. *JAMA* 1997;277:1794–801.
  13. Steckelberg JM, Murphy JG, Ballard D et al. Emboli in infective endocarditis: the prognostic value of echocardiography. *Ann Intern Med* 1991;114:635–40.
  14. Li W, Somerville J. Infective endocarditis in the grown-up congenital heart (GUCH) population. *Eur Heart J* 1998;19:166–73.
  15. Bonow RO, Carabello B, deLeon AC et al. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 1998;32:1486–588.
  16. The Endocarditis Working Group of the International Society of Chemotherapy. Lepout C. Antibiotic prophylaxis for infective endocarditis. *Clin Microbiol Infect* 1998;4(Suppl 3):S56–61.
  17. Grieve DA, Chen SC, Chapuis PH et al. Streptococcus bovis bacteraemia: its significance for the colorectal surgeon. *Aust NZ J Surg* 1990;60:550–2.
  18. Lacassin F, Hoen B, Lepout C et al. Procedures associated with infective endocarditis in adults. A case control study. *Eur Heart J* 1995;16:1968–74.
  19. Steckelberg JM, Khandheria BK, Anhalt JP et al. Prospective evaluation of the risk of bacteremia associated with transesophageal echocardiography. *Circulation* 1991;84:177–80.
  20. Ho H, Zuckerman MJ, Wasseem C. A prospective controlled study of the risk of bacteremia in emergency sclerotherapy of esophageal varices. *Gastroenterology* 1991;101:1642–8.
  21. Dajani AS, Bawdon RE, Berry MC. Oral amoxicillin as prophylaxis for endocarditis: what is the optimal dose? *Clin Infect Dis* 1994;18:157–60.
  22. Rouse MS, Steckelberg JM, Brandt CM et al. Efficacy of azithromycin or clarithromycin for the prophylaxis of viridans group streptococcus experimental endocarditis. *Antimicrob Agents Chemother* 1997;41:1673–6.
  23. Bayer AS, Nelson RJ, Slama TG. Current concepts in prevention of prosthetic valve endocarditis. *Chest* 1990;97:1203–7.
  24. Cheitlin MD, Alpert JS, Armstrong WF et al. ACC/AHA guidelines for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 1997;95:1686–744.
  25. Mügge A, Daniel WG, Frank G et al. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. *J Am Coll Cardiol* 1989;14:631–8.
  26. Job FP, Franke S, Lethen H et al. Incremental value of biplane and multiplane transesophageal echocardiography for the assessment of active infective endocarditis. *Am J Cardiol* 1995;75:1033–7.
  27. Vuille C, Nidorf M, Weyman AE et al. Natural history of vegetations during successful medical treatment of endocarditis. *Am Heart J* 1994;128:1200–9.
  28. DeCastro S, d'Amati G, Cartoni D et al. Valvular perforation in left-sided infective endocarditis: a prospective echocardiographic evaluation and clinical outcome. *Am Heart J* 1997;134:656–64.
  29. Erbel R, Liu F, Ge J, Rohmann S et al. Identification of high-risk subgroups in infective endocarditis and the role of echocardiography. *Eur Heart J* 1995;16:588–602.
  30. Leung DY, Cranney GB, Hopkins AP et al. Role of transesophageal echocardiography in the diagnosis and management of aortic root abscess. *Br Heart J* 1994;72:175–81.
  31. Choussat R, Thomas D, Isnard R et al. Perivalvular abscesses associated with endocarditis. Clinical features and prognostic factors of overall survival in a series of 233 cases. *Eur Heart J* 1999;20:232–41.
  32. Piper C, Hetzer R, Körfer F et al. The importance of secondary mitral valve involvement in primary aortic valve endocarditis: The mitral kissing vegetation. *Eur Heart J* 2002;23:79–86.
  33. Freedberg RS, Goodkin GM, Perez JL et al. Valve strands are strongly associated with systemic embolization: A transesophageal echocardiographic study. *J Am Coll Cardiol*. 1995;26:1709–12.
  34. Vilacosta I, Sarriá C, San Román JA et al. Usefulness of transesophageal echocardiography for diagnosis of infected transvenous permanent pacemakers. *Circulation* 1994;89:2684–7.
  35. Victor F, De Place C, Camus C et al. Pacemaker lead infection: echocardiographic features, management, and outcome. *Heart* 1999;81:82–7.
  36. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. *Clin Microbiol Rev* 1997;10:444–65.
  37. Pazin GJ, Saul S, Thompson E. Blood culture positivity. Suppression by outpatient antibiotic therapy in patients with bacterial endocarditis. *Arch Int Med* 1982;142:263–8.
  38. The Endocarditis Working Group of the International Society of Chemotherapy. Gutschik E. Microbiological recommendations for the diagnosis and follow-up of infective endocarditis. *Clin Microbiol Infect* 1998;4(Suppl 3):S10–6.
  39. Von Reyn CF, Levy BS, Arbeit RD et al. Infective endocarditis: an analysis based on strict case definitions. *Ann Intern Med* 1981;94:505–18.
  40. The Duke Endocarditis Service. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: Utilization of specific echocardiographic findings. *Am J Med* 1994;96:200–9.
  41. Bayer AS, Ward JI, Ginzton LE et al. Evaluation of new clinical criteria for the diagnosis of infective endocarditis. *Am J Med* 1994;96:211–9.
  42. Habib G, Derumeaux G, Avierinos JF et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. *J Am Coll Cardiol* 1999;33:2023–9.
  43. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis* 2000;30:633–8.
  44. Wilson ML, Mirrett S, Reller LB et al. Recovery of clinically important microorganisms from in the Bact/Alert blood culture system does not require testing for seven days. *Diagn Microbiol Infect Dis* 1993;16:31–4.
  45. Burnie JP, Clark I. Immunoblotting in the diagnosis of culture negative endocarditis caused by streptococci and enterococci. *J Clin Pathol* 1995;48:1130–6.
  46. Siegman-Igra Y, Kaufman O, Keysary A et al. Q fever endocarditis in Israel and a worldwide review. *Scand J Infect Dis* 1997;29:41–9.
  47. Woods GL, Wood RP, Shaw BW Jr. Aspergillus endocarditis in patients without prior cardiovascular surgery: report of a case in a liver transplant recipient and review. *Rev Infect Dis* 1989;11:263–72.
  48. Goldenberger D, Künzli A, Vogt P et al. Molecular diagnosis of bacterial endocarditis using broad-range PCR amplification and direct sequencing. *J Clin Microbiol* 1997;35:2733–9.
  49. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and  $\beta$ -lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. *Antimicrob Agents Chemother* 1999;43:1747–53.



50. Kim WJ, Weinstein RA, Hayden MK. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. *J Infect Dis* 1999; **179**:163–71.
51. Working Party of the British Society for Antimicrobial Chemotherapy. Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis. *Heart* 1998; **79**:207–10.
52. Shanson DC. New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. *J Antimicrob Chemother* 1998; **42**:292–6.
53. The Endocarditis Working Group of the International Society for Chemotherapy. Wilson WR. Antibiotic treatment of infective endocarditis due to viridans streptococci, enterococci, and other streptococci. *Clin Microbiol Infect* 1998; **4**(Suppl 3):S17–26.
54. Bugnon D, Potel G, Xiong YQ et al. In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a *Serratia marcescens* endocarditis experimental model. *Antimicrob Agents Chemother* 1996; **40**:1164–9.
55. Sexton DJ, Tenenbaum MJ, Wilson WR et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. *Clin Infect Dis* 1998; **27**:1470–4.
56. Hessen MT, Pitsakis PG, Levison ME. Postantibiotic effect of penicillin plus gentamicin versus *Enterococcus faecalis* in vitro and in vivo. *Antimicrob Agents Chemother* 1989; **33**:608–11.
57. Renneberg J, Niemann LL, Gutschik E. Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents. *J Antimicrob Chemother* 1997; **39**:135–40.
58. Moellering RCJ. Treatment of endocarditis caused by resistant streptococci. In: Horstkotte D, Bodnar E, editors. *Infective Endocarditis*. Aylesbury, Bucks, England: ICR Publishers; 1991, p. 102–9.
59. On behalf of the OHPAT UK Workshop. Nathwani D, Conlon C. Out-patient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party. *Clin Microbiol Infect* 1998; **4**:537–51.
60. The Endocarditis Working Group of the International Society for Chemotherapy. Francioli PB, Stamboulian D. Outpatient treatment of infective endocarditis. *Clin Microbiol Infect* 1998; **4**(Suppl 3):S47–55.
61. Piper C, Wiemer M, Schulte HD et al. Stroke is not a contraindication for urgent valve replacement in acute infective endocarditis. *J Heart Valve Dis* 2001; **10**:703–11.
62. Roder BL, Wandall DA, Frimodt-Moller N et al. Clinical features of *Staphylococcus aureus* endocarditis: a 10-year experience in Denmark. *Arch Intern Med* 1999; **159**:462–9.
63. Tornos P., Almirante B, Mirabet S et al. Infective endocarditis due to *Staphylococcus aureus*: deleterious effect of anticoagulant therapy. *Arch Intern Med* 1999; **159**:473–5.
64. Bonow RO, Carabello B, de Leon AC Jr. et al. Guidelines for the management of patients with valvular heart disease: executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). *Circulation* 1998; **98**:1949–84.
65. Etienne J, Eykin SJ. Increase in native valve endocarditis caused by coagulase-negative staphylococci. An Anglo-French clinical and microbiological study. *Br Heart J* 1990; **64**:381–4.
66. Wilson WR, Karchmer AW, Dajani AS et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. *JAMA* 1995; **274**:1706–13.
67. Gutschik E. New developments in the treatment of infective endocarditis and infective cardiovascularitis. *Int J Antimicrob Agents* 1999; **13**:79–83.
68. Ellis M. Fungal endocarditis. *J Infect* 1997; **35**:99–103.
69. Piper C, Körfer R, Horstkotte D. Prosthetic valve endocarditis. *Heart* 2001; **85**:590–3.
70. Lutwick LI, Vaghjimal A, Connolly MW. Postcardiac surgery infections. *Crit Care Clin* 1998; **14**:221–50.
71. Smart FW, Naftel DC, Costanzo MR et al. Risk factors for early cumulative and fatal infections after heart transplantation: A multi-institutional study. *J Heart Lung Transplant* 1996; **15**:329–41.
72. Mull DH, Wait MA, Page RL et al. Importance of complete system removal of infected cardioverter-defibrillators. *Ann Thorac Surg* 1995; **60**:704–6.
73. Fischer SA, Trenholme GW, Costanzo MR et al. Infectious complications in left ventricular assist device recipients. *Clin Infect Dis* 1997; **24**:18–23.
74. McCarthy PM, Schmitt SK, Vargo RL et al. Implantable LVAD infections: Implications for permanent use of the device. *Ann Thorac Surg* 1996; **61**:359–73.
75. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. *Ann Intern Med* 1993; **119**:1017–28.
76. Bisbe J, Miró JM, Latorre X et al. Disseminated candidiasis in addicts who use brown heroin. Report of 83 cases and review. *Clin Infect Dis* 1992; **15**:910–23.
77. Carbon C and the Endocarditis Working Group of the International Society of Chemotherapy. Rubinstein E. Staphylococcal endocarditis—recommendations for therapy. *Clin Microbiol Infect* 1998; **4**(Suppl 3):S27–33.
78. Ribera E, Gomez-Jimenez J, Cortes E et al. Effectiveness of cloxacillin with or without gentamicin in short-term therapy for right-sided *Staphylococcus aureus* endocarditis. A randomized, controlled trial. *Ann Intern Med* 1996; **125**:969–74.
79. Elkayam U. Pregnancy and cardiovascular disease. In: Braunwald E, editor. *Heart Disease*. 5th edn Philadelphia: Saunders; 1997, p. 1843–64.
80. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. *Clin Pharmacokin* 1997; **33**:328–43.
81. Dashe JS, Gilstrap LC. Antibiotic use in pregnancy. *Obstet Gynecol Clin North Am* 1997; **24**:617–29.
82. Shotan A, Widerhorn J, Hurst A et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use. *Am J Med* 1994; **96**:451–6.
83. Blumberg EA, Robbins N, Adimora A et al. Persistent fever in association with infective endocarditis. *Clin Infect Dis* 1992; **15**:983–90.
84. Conlon PJ, Jefferies F, Krigman HR et al. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. *Clin Nephrol* 1998; **49**:96–101.
85. Hart RG, Foster JW, Luther MF et al. Stroke in infective endocarditis. *Stroke* 1990; **21**:695–700.
86. DiSalvo G, Habib G, Pergola V et al. Echocardiography predicts embolic events in infective endocarditis. *J Am Coll Cardiol* 2001; **37**:1069–76.
87. Tischler MD, Vaitkus PT. The ability of vegetation size on echocardiography to predict clinical complications: a meta-analysis. *J Am Soc Echocardiogr* 1997; **10**:562–8.
88. De Castro S, Magni G, Beni S et al. Role of transthoracic and transesophageal echocardiography in predicting embolic events in patients with active infective endocarditis involving native cardiac valves. *Am J Cardiol* 1997; **80**:1030–4.
89. Kupferwasser LI, Yeaman MR, Shapiro SM et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination and frequency of embolic events in experimental *Staphylococcus aureus* endocarditis through antiplatelet and antibacterial effects. *Circulation* 1999; **99**:2791–7.
90. Parrino PE, Kron IL, Ross SD et al. Does a focal neurologic deficit contraindicate operation in a patient with endocarditis? *Ann Thorac Surg* 1999; **67**:59–64.
91. Moon MR, Stinson EB, Miller DC. Surgical treatment of endocarditis. *Prog Cardiovasc Dis* 1997; **40**:239–64.
92. Horstkotte D, Schulte HD, Niehues R et al. Diagnostic and therapeutic considerations in acute, severe mitral regurgitation: experience in 42 consecutive patients entering the intensive care unit with pulmonary edema. *J Heart Valve Dis* 1993; **2**:512–22.
93. Arbulu A, Asfaw I. Tricuspid valvectomy without prosthetic replacement. Ten years of clinical experience. *J Thorac Cardiovasc Surg* 1981; **82**:684–91.
94. Korman TM, Spelman DW, Perry GJ et al. Acute glomerulonephritis associated with acute Q fever: Case report and review of the renal complications of *Coxiella burnetii* infections. *Clin Infect Dis* 1998; **26**:359–64.

95. DiNubile MJ. Heart block during bacterial endocarditis: a review of the literature and guidelines for surgical intervention. *Am J Med Sci* 1984;**287**:30–2.
96. Mansur AJ, Dal Bo CM, Fukushima JT et al. Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis. *Am Heart J* 2001;**141**:78–86.
97. Pansini S, di Summa M, Patane F et al. Risk of recurrence after reoperation for prosthetic valve endocarditis. *J Heart Valve Dis* 1997;**6**:84–7.
98. Verheul H, Van den Brink RB, van Vreeland T et al. Effects of changes in management of active infective endocarditis on outcome in a 25-year period. *Am J Cardiol* 1993;**72**:682–7.
99. Tornos MP, Permanyer-Miralda G, Olona M et al. Long term complications of native valve infective endocarditis in non addicts. A 15-year follow-up study. *Ann Intern Med* 1992;**117**:567–72.
100. Edwards MB, Ratnatunga CP, Dore CJ et al. Thirty-day mortality and long-term survival following surgery for prosthetic endocarditis: a study from the UK heart valve registry. *Eur J Cardiothorac Surg* 1998;**14**:156–64.
101. Trouillet JL, Hoen B, Battik R et al. Splenic involvement in infectious endocarditis. Association for the Study and Prevention of Infectious Endocarditis. *Rev Med Interne* 1999;**20**:258–63.
102. David TE. Surgical management of aortic root abscess. *J Card Surg* 1997;**12**:262–9.
103. Prat A, Fabre OH, Vincentelli A et al. Ross operation and mitral homograft for aortic and tricuspid valve endocarditis. *Ann Thorac Surg* 1998;**65**:1450–2.
104. Guerra JM, Tornos MP, Permanyer-Miralda G et al. Long term results of mechanical prostheses for treatment of active infective endocarditis. *Heart* 2001;**86**:63–8.
105. Klug D, Lacroix D, Savoye C et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. *Circulation* 1997;**95**:2098–107.